05.20.11
Accovion has expanded with a new subsidiary in the UK and has appointed Carl Naraynassamy as managing director. The expansion is part of Accovion’s strategic plan to formalize activities in several European countries by establishing additional subsidiaries and to offer its clients a broader spectrum of country-specific clinical research expertise.
Ivana Waller, Accovion’s chief operating officer, said, “The UK has always represented a key strategic territory for Accovion. In addition, with our increasing regulatory portfolio, our growing involvement in device pharmacovigilance and health economics, it had become imperative for us to be firmly implanted in London. Our new subsidiary consolidates our presence in Europe and affords us a sure platform to access the considerable local clinical research talent and respond even better to our clients’ growing needs.”
“We are very pleased to bring on board an experienced Mr. Naraynassamy, who is well respected for his contributions to the fields of clinical research and pharmaceutical medicine education globally. I am confident that with his vision, business acumen and clinical research expertise, Accovion’s operations in the UK will continue to prosper,” added Ms. Waller.
Accovion supports local and global projects for the pharmaceutical, biotechnology and medical device industries, including project planning and management, clinical trial execution, clinical monitoring, data management, adverse event management including post-marketing surveillance, biostatistics and statistical programming, medical writing and electronic publishing.
Ivana Waller, Accovion’s chief operating officer, said, “The UK has always represented a key strategic territory for Accovion. In addition, with our increasing regulatory portfolio, our growing involvement in device pharmacovigilance and health economics, it had become imperative for us to be firmly implanted in London. Our new subsidiary consolidates our presence in Europe and affords us a sure platform to access the considerable local clinical research talent and respond even better to our clients’ growing needs.”
“We are very pleased to bring on board an experienced Mr. Naraynassamy, who is well respected for his contributions to the fields of clinical research and pharmaceutical medicine education globally. I am confident that with his vision, business acumen and clinical research expertise, Accovion’s operations in the UK will continue to prosper,” added Ms. Waller.
Accovion supports local and global projects for the pharmaceutical, biotechnology and medical device industries, including project planning and management, clinical trial execution, clinical monitoring, data management, adverse event management including post-marketing surveillance, biostatistics and statistical programming, medical writing and electronic publishing.